Mirvie announces results from largest molecular study in pregnancy and clinical validation of simple blood test to predict risk for preeclampsia months before symptoms
APRIL 8, 2025
Mirvie announced results of a breakthrough study published in Nature Communications, revealing new advances in the biological understanding of hypertensive disorders of pregnancy (HDP), including preeclampsia - a leading cause of maternal morbidity and mortality as well as preterm birth. Researchers used data from more than 9,000 pregnancies within the multi-center Mirvie-sponsored Miracle of Life prospective study to discover and validate RNA signatures capable of distinguishing between severe and mild hypertensive disorders of pregnancy, including preeclampsia, months before symptoms occur. The paper also validates the predictive performance of Mirvie’s simple blood test to predict preeclampsia early, at 17.5 to 22 weeks gestational age, in pregnancies without any pre-existing high-risk conditions.
Read the Publication
